PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines

[1]  P. Bosco,et al.  PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease , 2013, Human Cell.

[2]  J. McMurray,et al.  Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. , 2011, Blood.

[3]  Eric P Kaldjian,et al.  Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. , 2010, Genes & cancer.

[4]  P. Walsh,et al.  Chemoprevention of prostate cancer. , 2010, The New England journal of medicine.

[5]  J. Walczak,et al.  Prostate cancer: a practical approach to current management of recurrent disease. , 2007, Mayo Clinic proceedings.

[6]  A. Farré,et al.  Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. , 2005, The Journal of urology.

[7]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[8]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[9]  S. Snyder,et al.  Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Gallagher,et al.  Prostate cancer: 3. Individual risk factors. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[11]  O. Cussenot,et al.  Functional expression of sv40 in normal human prostatic epithelial and fibroblastic cells - differentiation pattern of nontumorigenic cell-lines. , 1995, International journal of oncology.

[12]  O. Cussenot,et al.  Immortalization of human adult normal prostatic epithelial cells by liposomes containing large T-SV40 gene. , 1991, The Journal of urology.

[13]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[14]  M. Hottiger,et al.  The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. , 2008, Frontiers in bioscience : a journal and virtual library.

[15]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[16]  P. Alken,et al.  Prostate cancer therapy: standard management, new options and experimental approaches. , 2005, Anticancer research.

[17]  N. Guseva,et al.  Death receptor‐induced cell death in prostate cancer , 2004, Journal of cellular biochemistry.

[18]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[19]  O. Kucuk.  Chemoprevention of prostate cancer : Clinical and translational research in prostate cancer, part II , 2002 .

[20]  M. Marcelli,et al.  Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.

[21]  Y. Lazebnik,et al.  Caspases: enemies within. , 1998, Science.

[22]  T H Beaty,et al.  Family history and the risk of prostate cancer , 1990, The Prostate.